Your Article Summary
See Latest ArticlesPerspective of Botox for treatment of male lower urinary tract symptoms
Current Opinion in Urology, 01/06/09
Ilie CP et al. - Although the clinical series demonstrate efficacy of minimum 6 months, more studies are necessary in order to identify the mechanisms by which BTX-A affects the prostate, the ideal dose and the duration of effect. BTX-A use in prostate disease is currently 'off-label'.
Related Articles
Lower urinary tract dysfunction in MS: management in the community
British Journal of Community Nursing, 11/17/09
Relevance Score: 89%
Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study
World Journal of Urology, 11/13/09
Relevance Score: 89%
Gender and Age Differences in the Perception of Bother and Health Care Seeking for Lower Urinary Tract Symptoms: Results from the Hospitalised and Outpatients Profile and Expectations Study
European Urology, 11/10/09
Relevance Score: 89%
Bladder Problems May Often Be Related to Mental Health
Internet Source, 10/27/09
Relevance Score: 89%
Is ultrasound estimation of bladder weight a useful tool in the assessment of patients with lower urinary tract symptoms
International Urogynecology Journal, 10/07/09
Relevance Score: 89%
Today in Men`s Health...keeping you current
Receive free subspecialty "5-minute updates" via email
Male breast cancer: A population-based comparison with female breast cancer
Journal of Clinical Oncology, 12/11/09
Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: A double-blind, randomised trial
The Lancet Oncology - Online First, 12/09/09
Sexual Dysfunction in an Internet Sample of U.S. Men Who Have Sex with Men
The Journal of Sexual Medicine, 12/09/09